EP2525660A4 - Formulation à libération modifiée et procédés d'utilisation - Google Patents

Formulation à libération modifiée et procédés d'utilisation

Info

Publication number
EP2525660A4
EP2525660A4 EP11735033.0A EP11735033A EP2525660A4 EP 2525660 A4 EP2525660 A4 EP 2525660A4 EP 11735033 A EP11735033 A EP 11735033A EP 2525660 A4 EP2525660 A4 EP 2525660A4
Authority
EP
European Patent Office
Prior art keywords
methods
release formulation
modified release
modified
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11735033.0A
Other languages
German (de)
English (en)
Other versions
EP2525660A1 (fr
Inventor
Biljana Nadjsombati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VALEANT PHARMACEUTICALS INTERNATIONAL
VALEANT PHARMACEUTICALS INT
Original Assignee
VALEANT PHARMACEUTICALS INTERNATIONAL
VALEANT PHARMACEUTICALS INT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47042234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2525660(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/690,889 external-priority patent/US20100323015A1/en
Priority claimed from US12/691,680 external-priority patent/US20100323016A1/en
Application filed by VALEANT PHARMACEUTICALS INTERNATIONAL, VALEANT PHARMACEUTICALS INT filed Critical VALEANT PHARMACEUTICALS INTERNATIONAL
Publication of EP2525660A1 publication Critical patent/EP2525660A1/fr
Publication of EP2525660A4 publication Critical patent/EP2525660A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11735033.0A 2010-01-20 2011-01-18 Formulation à libération modifiée et procédés d'utilisation Withdrawn EP2525660A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/690,889 US20100323015A1 (en) 2008-07-18 2010-01-20 Modified release formulation and methods of use
US12/691,680 US20100323016A1 (en) 2008-07-18 2010-01-21 Modified release formulation and methods of use
PCT/US2011/021498 WO2011090923A1 (fr) 2010-01-21 2011-01-18 Formulation à libération modifiée et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2525660A1 EP2525660A1 (fr) 2012-11-28
EP2525660A4 true EP2525660A4 (fr) 2013-08-07

Family

ID=47042234

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11735033.0A Withdrawn EP2525660A4 (fr) 2010-01-20 2011-01-18 Formulation à libération modifiée et procédés d'utilisation

Country Status (6)

Country Link
EP (1) EP2525660A4 (fr)
BR (1) BR112012018173A2 (fr)
CL (1) CL2012002014A1 (fr)
CO (1) CO6592107A2 (fr)
EA (1) EA201290663A1 (fr)
MX (1) MX2012008475A (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066081A2 (fr) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Formulations pharmaceutiques
US20060251721A1 (en) * 2003-09-26 2006-11-09 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
WO2008066900A1 (fr) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International Analogues de 1,4-diamino rétigabine bicycliques en tant que modulateurs de canaux potassiques
WO2010009433A1 (fr) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Formulation à libération modifiée et procédés d'utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066081A2 (fr) * 2000-03-08 2001-09-13 Awd.Pharma Gmbh & Co.Kg Formulations pharmaceutiques
US20060251721A1 (en) * 2003-09-26 2006-11-09 Evangeline Cruz Controlled release formulations of opioid and nonopioid analgesics
WO2008066900A1 (fr) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International Analogues de 1,4-diamino rétigabine bicycliques en tant que modulateurs de canaux potassiques
WO2010009433A1 (fr) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Formulation à libération modifiée et procédés d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011090923A1 *

Also Published As

Publication number Publication date
EA201290663A1 (ru) 2013-03-29
EP2525660A1 (fr) 2012-11-28
MX2012008475A (es) 2013-11-01
CL2012002014A1 (es) 2013-04-05
BR112012018173A2 (pt) 2017-08-29
CO6592107A2 (es) 2013-01-02

Similar Documents

Publication Publication Date Title
HK1243417A1 (zh) 吡啶酮和氮雜吡啶酮化合物及使用方法
EP2611413A4 (fr) Compositions pour la peau et leurs applications
EP2536756A4 (fr) Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
EP2584897A4 (fr) Compositions contenant du resvératrol et procédés d'utilisation
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2654726A4 (fr) Formulations de dispersions solides et leurs procédés d'utilisation
HK1202244A1 (en) Prebiotic formulations and methods of use
EP2563372A4 (fr) Formulations prébiotiques et méthodes d'utilisation
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2624790A4 (fr) Dispositif intervertébral et ses procédés d'utilisation
EP2536283A4 (fr) Dérivés de phényl-hétéroaryle et procédés d'utilisation de ceux-ci
EP2596112A4 (fr) Compositions d'acétylcystéine et méthodes d'utilisation correspondantes
EP2579831A4 (fr) Distributeur et procédés d'utilisation
IL221043A0 (en) Modified release formulation and methods of use
HK1181316A1 (en) Notch1 binding agents and methods of use thereof notch1
ZA201206462B (en) Extended release formulations of rasagiline and uses thereof
EP2548859A4 (fr) Procédés de préparation d'une méthyl-d3-amine et de sels de celle-ci
ZA201102518B (en) Modified release formulation and methods of use
EP2536709A4 (fr) Inhibiteurs de la prolylhydroxylase et procédés d'utilisation
HK1189501A1 (zh) 抗體組合物及使用方法
PT2521445T (pt) Formulação e utilização da mesma
EP2603221A4 (fr) Ggf2 et procédés d'utilisation
ZA201406267B (en) Controlled release compositions and their methods of use
EP2558113A4 (fr) Compositions thérapeutiques de serca2 et méthodes d'utilisation
EP2649096A4 (fr) Compositions d'hémoglobine et procédés d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120816

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130708

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/27 20060101ALI20130702BHEP

Ipc: A61K 9/20 20060101ALI20130702BHEP

Ipc: A61K 9/16 20060101ALI20130702BHEP

Ipc: A61K 9/28 20060101AFI20130702BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150801